Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25906768 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL19090252 | 0.81 | — | — | |
| SCHEMBL16997031 | 0.81 | ARG1 (0.32) | — | |
| SCHEMBL20224763 | 0.81 | ARG1 (0.32) | — | |
| SCHEMBL12385835 | 0.78 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL12384238 | 0.78 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL12384748 | 0.78 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL25978859 | 0.78 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL30849837 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL12938791 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20210015948-A1 | MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING | THE GENERAL HOSPITAL CORPORATION | 2021-01-21 | — | — | US | disclosed |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015948-A1 | MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING | MPI, MAG, MNS1 | SMN1; SMN2 128/4885LMNA 3010/4885 |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SMN1; SMN2 2604/4885LMNA 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.